Sarepta Gets Breathing Room in $700 Million Debt Restructure

Sarepta Therapeutics Inc. landed a deal with investors to restructure around $700 million of debt, giving the company a reprieve as it recovers from a controversy over its gene therapy.

Prior to the deal, Sarepta had been staring down $1.2 billion of debt and warned in filings earlier this year that its cash flow may not be enough to pay that obligation, which was due in 2027.